CRES 102
Alternative Names: BDX-102; CRES-102Latest Information Update: 24 Jan 2023
At a glance
- Originator Cresence
- Class Neuropeptides; Neuroprotectants
- Mechanism of Action Myelin protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Guillain-Barre syndrome
Most Recent Events
- 24 Jan 2023 Bioasis plans to file for ODD designation in Guillain-Barre syndrome, by Q2 of 2023 (Bioasis pipeline, January 2023)
- 16 Oct 2022 Preclinical trials in Guillain Barre syndrome in Norway (unspecified route) (Cresence pipeline, October 2022)